Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
TiNivo: tivozanib-nivolumab bij patiënten met gemetastaseerd niercelcarcinoom
jan 2021 | Uro-oncologie